Paul Hastings Advised Underwriters on CymaBay Therapeutics, Inc.’s $258.75 Million Follow-On Offering
September 19, 2023
Paul Hastings LLP advised Piper Sandler and Raymond James as representatives of the several underwriters in connection with CymaBay Therapeutics, Inc.’s $258.75 million follow-on offering of common stock and pre-funded warrants, including full exercise of the underwriters’ option to purchase additional shares. CymaBay Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.
More details on the transaction can be found here.
About Paul Hastings
>With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.